{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:23:32Z","timestamp":1788870212996,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.rmed.2012.10.022","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T09:48:08Z","timestamp":1354787288000},"page":"223-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use"],"prefix":"10.1016","volume":"107","author":[{"given":"Marc","family":"Decramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Kornmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"McBryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2012.10.022_bib1","series-title":"Global strategy for diagnosis, management, and prevention of COPD","year":"2011"},{"key":"10.1016\/j.rmed.2012.10.022_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-10-11","article-title":"Efficacy and safety of indacaterol 150\u00a0\u03bcg once-daily in COPD: a double-blind, randomised, 12-week study","volume":"10","author":"Feldman","year":"2010","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled \u03b22-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2012.10.022_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2012.10.022_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardization of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2012.10.022_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2012.10.022_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0895-4356(02)00589-9","article-title":"Meaningful effect size and patterns of response of the transition dyspnea index","volume":"56","author":"Witek","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rmed.2012.10.022_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2012.10.022_bib10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2012.10.022_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2012.10.022_bib12","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2012.10.022_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-10-59","article-title":"Efficacy of salmeterol\/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study","volume":"10","author":"Jenkins","year":"2009","journal-title":"Respir Res"},{"key":"10.1016\/j.rmed.2012.10.022_bib14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1164\/rccm.201105-0831OC","article-title":"The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort","volume":"184","author":"Casanova","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/thx.2009.133355","article-title":"Treatment of COPD: the sooner the better?","volume":"65","author":"Decramer","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2012.10.022_bib16","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","article-title":"Changes in forced expiratory volume in 1 second over time in COPD","volume":"365","author":"Vestbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1378\/chest.09-2498","article-title":"Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD","volume":"138","author":"Williams","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2012.10.022_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4104\/pcrj.2010.00059","article-title":"Disease severity and symptoms among patients receiving monotherapy for COPD","volume":"20","author":"Dransfield","year":"2011","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.rmed.2012.10.022_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-12-54","article-title":"Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches","volume":"12","author":"Renard","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.rmed.2012.10.022_bib21","unstructured":"Meeting materials of the March 8, 2011, meeting of the Pulmonary-Allergy Drugs Advisory Committee, Food and Drug Administration. At: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Pulmonary-AllergyDrugsAdvisoryCommittee\/UCM248744.pdf [accessed 10.9.12]."},{"key":"10.1016\/j.rmed.2012.10.022_bib22","series-title":"Global strategy for diagnosis, management, and prevention of COPD","year":"2010"},{"key":"10.1016\/j.rmed.2012.10.022_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1183\/09031936.00190908","article-title":"Inhaled corticosteroids in COPD: the case against","volume":"34","author":"Suissa","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2012.10.022_bib24","doi-asserted-by":"crossref","first-page":"w13053","DOI":"10.4414\/smw.2010.13053","article-title":"General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study","volume":"140","author":"Jochmann","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.rmed.2012.10.022_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.rmr.2009.08.002","article-title":"COPD routine management in France: are guidelines used in clinical practice?","volume":"27","author":"Jebrak","year":"2010","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmed.2012.10.022_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/fampra\/cmn006","article-title":"Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study","volume":"25","author":"Lucas","year":"2008","journal-title":"Fam Pract"},{"key":"10.1016\/j.rmed.2012.10.022_bib27","first-page":"13","article-title":"Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study","volume":"15","author":"Bourbeau","year":"2008","journal-title":"Can Respir J"},{"key":"10.1016\/j.rmed.2012.10.022_bib28","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1185\/03007995.2011.583230","article-title":"Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis","volume":"27","author":"Fitch","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmed.2012.10.022_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1513\/pats.200701-024FM","article-title":"Inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"4","author":"Suissa","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2012.10.022_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/COPD.S6942","article-title":"An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"5","author":"Singh","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2012.10.022_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1164\/rccm.200611-1630OC","article-title":"Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia","volume":"176","author":"Ernst","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2012.10.022_bib35","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2008.717","article-title":"Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Drummond","year":"2008","journal-title":"JAMA"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611112004088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611112004088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:25:55Z","timestamp":1760613955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611112004088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0954611112004088"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2012.10.022","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2012.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}